Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Chao LiuRuiqi LiuBojun WangJie LianYang YaoHaoxiu SunChunhui ZhangLin FangXin GuanJiaqi ShiShuling HanFei ZhanShengnan LuoYuanfei YaoTongsen ZhengYan-Qiao ZhangPublished in: Journal for immunotherapy of cancer (2021)
IL-17A increases PD-L1 expression through the p65/NRF1/miR-15b-5p axis and promotes resistance to anti-PD-1 therapy. Blocking IL-17A improved the efficacy of anti-PD-1 therapy in MSS CRC murine models. IL-17A might serve as a therapeutic target to sensitize patients with MSS CRC to ICI therapy.